Business Context and Reporting Period
Company: Lyell Immunopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 20, 2025
Event: Unregistered Sale of Equity Securities (Item 3.02)
The Company reported the completion of a milestone payment obligation arising from its acquisition of ImmPACT Bio USA Inc. (ImmPACT) under a Merger Agreement dated October 24, 2024.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a specific equity issuance event.
- Equity Issuance: 625,000 shares of Company Common Stock (post 1-for-20 reverse stock split).
- Recipient: ImmPACT securityholders.
- Regulatory Basis: Exemption under Section 4(a)(2) of the Securities Act of 1933.
Material Changes
The material change reported is the achievement of a clinical milestone for ImmPACT's next-generation CAR T-cell product candidate. This achievement triggered the entitlement of ImmPACT securityholders to receive the Equity Milestone Shares as defined in the Merger Agreement.
Guidance, Outlook, and Risks
Management Commentary: The Company delivered formal notice on June 20, 2025, confirming the milestone achievement and the subsequent issuance of shares.
Risks and Contingencies:
- The Equity Milestone Shares are unregistered and may not be offered or sold in the United States absent registration or an applicable exemption.
- The issuance is a private placement without general solicitation or advertising.
- Adjustments may be made to the share count to account for cash payments made to certain securityholders in lieu of fractional shares.
Investor Verification Checklist
- Verify the specific clinical milestone achieved for the ImmPACT CAR T-cell product candidate.
- Confirm the impact of the 625,000 share issuance on total outstanding shares and potential dilution.
- Review the Merger Agreement for details on future milestone payments or conditions.
- Check for any subsequent filings regarding the registration rights or resale restrictions of the issued shares.